IP Library › Granted Patent US 11,648,237
Granted Patent B2
US 11,648,237 · App. 16/679,112 · Granted May 16, 2023

5HT agonists for treating disorders

Inventor: Scott C. Baraban (Novato, CA)
Assignee: The Regents of the University of California
A61K31/4184A61K31/137A61K31/496A61K31/55A61K31/7048A61K45/06A61P25/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,648,237
App. No.
16/679,112
Granted
May 16, 2023
Kind
B2
Abstract

Provided, inter alia, are methods for treating an epilepsy disorder using a 5HT receptor agonist, or a pharmaceutically acceptable salt thereof.

Claims (10)

1. A method of treating an infantile epileptic encephalopathy, said method comprising administering to a subject in need thereof a therapeutically effective amount of a 5HT receptor agonist, wherein said 5HT receptor agonist is clemizole, a clemizole analog, or a pharmaceutically acceptable salt thereof.

2. A method of treating an infantile epileptic encephalopathy, said method comprising administering to a subject in need thereof a therapeutically effective amount of a 5HT receptor agonist and an anti-epilepsy drug (AED), wherein said 5HT receptor agonist is clemizole, a clemizole analog, or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 or 2 , wherein said clemizole, a clemizole analog, or a pharmaceutically acceptable salt thereof inhibits compulsive behaviors or electrographic seizures in said subject.

4. The method of claim 1 or 2 , wherein said clemizole, a clemizole analog, or a pharmaceutically acceptable salt thereof reduces the incidence of unprovoked seizures in said subject when compared to the absence of said 5HT receptor agonist.

5. The method of claim 1 or 2 , wherein said clemizole, a clemizole analog, or a pharmaceutically acceptable salt thereof reduces or prevents myoclonus seizures or status epilepticus in said subject when compared to the absence of said 5HT receptor agonist.

6. The method of claim 2 , wherein said AED is acetazolamide, benzodiazepine, carbamazepine, clobazam, clonazepam, eslicarbazepine acetate, ethosuximide, ethotoin, felbamate, fenfluramine, fosphenytoin, gabapentin, ganaxolone, huperzine A, lacosamide, lamotrigine, levetiracetam, nitrazepam, oxcarbazepine, perampanel, piracetam, phenobarbital, phenytoin, potassium bromide, pregabalin, primidone, retigabine, rufinamide, valproic acid, sodium valproate, stiripentol, tiagabine, topiramate, vigabatrin, or zonisamide.

7. The method of claim 2 , wherein said AED is valproic acid, sodium valproate, clonazepam, ethosuximide, felbamate, gabapentin, carbamazepine, lamotrigine, levetiracetam, benzodiazepine, phenobarbital, oxcarbazepine, pregabalin, primidone, tiagabine, topiramate, potassium bromide, phenytoin, stiripentol, vigabatrin, or zonisamide.

8. The method of claim 2 , wherein said AED is valproic acid, sodium valproate, gabapentin, carbamazepine, oxcarbazepine, or vigabatrin.

9. The method of claim 1 or 2 , wherein said 5HT receptor agonist is not a serotonin reuptake inhibitor.

10. The method of claim 1 or 2 , wherein said pharmaceutically acceptable salt is clemizole HCl.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2023
From: BARABAN, SCOTT C.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 062758/0692 →
Continuity (3)
Division 15552784
Provisional Application 62120726 · Feb 25, 2015
Related Publication 20200147048A1 · May 14, 2020
Cited By (1)
US 12,447,144